| 24.73 0.31 (1.27%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 31.88 |
1-year : | 37.24 |
| Resists | First : | 27.29 |
Second : | 31.88 |
| Pivot price | 23.7 |
|||
| Supports | First : | 24.03 |
Second : | 22.01 |
| MAs | MA(5) : | 23.89 |
MA(20) : | 23.8  |
| MA(100) : | 21.48 |
MA(250) : | 18.94 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 86.9 |
D(3) : | 65.3 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 27.29 | Low : | 12.57 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DNLI ] has closed below upper band by 2.5%. Bollinger Bands are 45.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 24.98 - 25.07 | 25.07 - 25.15 |
| Low: | 24.12 - 24.23 | 24.23 - 24.33 |
| Close: | 24.55 - 24.71 | 24.71 - 24.85 |
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Thu, 06 Aug 2026
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Thu, 06 Aug 2026
Earnings Flash (DNLI) Denali Therapeutics Posts Q2 Loss of $0.68, vs. FactSet Est of $0.51 Loss - marketscreener.com
Thu, 06 Aug 2026
Earnings Flash (DNLI) Denali Therapeutics Inc. Reports Q2 Revenue $3.6M, vs. FactSet Est of $2.2M - marketscreener.com
Thu, 06 Aug 2026
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - The Manila Times
Thu, 06 Aug 2026
Denali Therapeutics (NASDAQ: DNLI) posts Q2 loss and launches AVLAYAH - Stock Titan
Thu, 06 Aug 2026
Denali Therapeutics (DNLI) Stock Could Be 20% Overvalued On Cash Flow Hopes - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 159 (M) |
| Shares Float | 144 (M) |
| Held by Insiders | 9.1 (%) |
| Held by Institutions | 105.1 (%) |
| Shares Short | 16,040 (K) |
| Shares Short P.Month | 15,410 (K) |
| EPS | -2.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.84 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -27 % |
| Return on Equity (ttm) | -49.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -2.57 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -412 (M) |
| Levered Free Cash Flow | -190 (M) |
| PE Ratio | -8.59 |
| PEG Ratio | 0 |
| Price to Book value | 4.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|